"HEB" Hemispherx BioPharma.... 第二帖

葉芬

對不起啊 Jochen，第一帖的HEB卡到
所以我從新開過一帖，希望你不介意。

資料 from m.i.k.e.

HEB 股东名单
wobushi  200
napster 5000
miku  0 （2/6/09 賣出）
blazechee 1000
cschiaw 5000
小锋 3500
mike 1000+2000=3000
叶芬 2500
Jochen 1000
ng33 2000
Liew 3000
Gnoit 1600
Ronniet 30000-1500=28500
Jochen 500
Ah Wee 1000
sunny仔  (呵呵 我可是借用m.i.k.e.的帖 Copy&aste來的）
Orochimaru ???

如果有漏掉或不对的,请通知.
(我这是没事找事做,帮大家做记录)



** 謝謝 m.i.k.e. 的寶貴時間。

[ 本帖最后由 葉芬 于 9-6-2009 09:05 AM 编辑 ]

miku

我昨天卖掉了。。不好意思，我太看近利乐~\(≧▽≦)/~啦啦啦

葉芬

“How high will the HEB price per share go once Ampligen gets approved?”

http://www.stockshaven.com/post- ... gen-pps-evaluation/

小鋒

昨晚真的起得莫名其妙～早上一醒来看到价位，还以为被批准了，谁知道什么也没有发生。
被这支股折磨了近一个月了，被FDA一拖再拖，真的很难顶。虽然每晚观看美股行情已成了我的乐趣，但还是希望快点公布啦～不要拖了，今晚就作个了断吧:@

葉芬

Hemispherx Biopharma: Hot and Likely to Get Hotter
by: David White June 03, 2009 | about stocks: HEB

http://seekingalpha.com/article/ ... ikely-to-get-hotter

葉芬

原帖由 小鋒 于 3-6-2009 04:34 PM 发表
昨晚真的起得莫名其妙～早上一醒来看到价位，还以为被批准了，谁知道什么也没有发生。
被这支股折磨了近一个月了，被FDA一拖再拖，真的很难顶。虽然每晚观看美股行情已成了我的乐趣，但还是希望快点公布啦～不要拖了 ...

承你貴言 ！

ng33

股东们，大家丢了吗？我的还在做古董。。。。。。。。。。。。。。。。

小鋒

我也快要作古了
目前还没打算套利卖掉，我挺看好Ampligen的潜力，现在只好赌一局大小了

cschiaw

我目前也是没打算卖掉，打算跟他赌一局大小!

Gnoit

开新帖也是好，小弟买了1600 ·1。71。
跟他博了。。。。

葉芬

HEB 好像好像有動作。。。

m.i.k.e

看来大家都信心十足,等着看HEB的底牌. 搞到我都想再加注.

今天学到一个新词,和大家分享. 希望 HEB 和 CTIC 都是 Tenbaggers.

Tenbaggers = 价格可以上涨十倍的股票.

What Does Tenbagger Mean?
A stock whose value increases ten times its purchase price. This expression was coined by Peter Lynch, one of the greatest investors of all time, in his book "One Up On Wall Street" (1989).  

Investopedia explains Tenbagger
These types of returns are considered once-in-a-lifetime investments. Some of the most famous examples of tenbaggers include now blue-chip stocks like Wal-Mart, Hewlett-Packard and General Electric. Many investors are constantly in search of the elusive tenbagger, but there isn't an exact science to discover tenbagger stocks. Generally, these explosive companies are smaller companies (market cap under $1 billion) with large potential markets. Over time, these companies grow into their potential markets, providing patient investors with handsome returns.

Question: What is the name of a stock that grows the equivalent of two tenbaggers?
Answer: A hundredbagger.
Question: Is it possible to find such as stock?
Answer: Yes! Since Monday 7/8/2003, exactly 3 years ago today when Hansen Natural (HANS) began its meteoric rise, the stock has appreciated 9,457% in price. In other words, $10,000 invested 3 years ago would be worth $946,000 today.

[ 本帖最后由 m.i.k.e 于 3-6-2009 11:27 PM 编辑 ]

葉芬

分享： Copy from Google Discussions

All the info U may know

Ampligen, also known as poly I:poly C12U, is an experimental
immunomodulatory double stranded RNA drug developed by HEMISPHERx
Biopharma of Philadelphia, Pennsylvania. Ampligen was first
synthesized in the 1970s and has been proposed and tested as a
treatment for many illnesses, but primarily chronic fatigue syndrome
(ME/CFS) and acquired immunodeficiency syndrome (AIDS).

Hemispherx reports that it completed a Phase III clinical trial for
CFS in 2004 and filed a new drug application (NDA) with the FDA for
approval of Ampligen in the treatment of CFS.[1] To date, it has not
been approved for marketing.[2]

History
Ampligen was developed after Merck & Co., in the 1960s, synthesized a
double-stranded RNA compound composed of inosinic and cytidylic acid
residues (poly I:poly C or poly I). Poly I inhibited tumor growth
by inducing interferon production. In the mid-1970s, William A.
Carter, a post-doctoral researcher at Johns Hopkins University,
modified the dsRNA molecule by adding uridylic acid molecules at
specific interval along the RNA chain. The new compound, called
Ampligen (for AMPLIfied GENetic activity) stimulated interferon
production like poly I, but was less toxic.[3]

Carter founded a company based upon the compound and licensed it from
Johns Hopkins. By the late 1980s, Carter and his company, HEM
Research, Inc., were pursuing human therapeutic uses for Ampligen, as
well as non-therapeutic uses, such as diagnostic testing for HIV and
protecting plants from pathogens.[4]

Ampligen was tested in clinical trials in America beginning in 1988,
after DuPont invested $30 million in Hemispherx. Initial success in a
small trial for AIDS treatment was followed by difficulties in
persuading the FDA to permit large scale trials. By 1991, it was
thought that the chance of approval for a large trial being conducted
in the USA had gone. Hemispherx then began to move clinical trials to
Canada and Belgium.[5]


In Belgium, Ampligen has been available for use since the drug's trial
beginning in May 1996. It has also been available under Canada's
Emergency Drug Release Program for both Chronic Fatigue Syndrome (CFS)
and HIV treatment since 1996, with marketing rights controlled by
Biovail Corporation International.[6] An agreement between the Spanish
company Esteve and Hemispherx in 2002 gave Esteve the rights to
perform clinical trials at their own cost in Spain, Portugal, and
Andorra.[7] Bioclones (PTY) Ltd, a UK based company, was granted the
exclusive marketing rights to Ampligen in the United Kingdom, Ireland,
and several countries in the Southern Hemisphere.[8] The marketing
agreement with Bioclones was terminated in 2005.[9] Over its
developmental history, Ampligen has received various designations,
including “orphan drug product” and “emergency compassionate cost
recovery sales authorization” both from the FDA and "promising"
clinical outcome recognition based on the evaluation of certain
summary clinical reports (AHRQ, Agency Health Research Quality).[10]

On December 3, 2007, the FDA deemed the NDA submitted by the company
on October 10, 2007 to be incomplete. Specifically eleven deficiencies
were noted in the Clinical Section and three in the Pre-Clinical
Section.

Ampligen acts by stimulating the innate immune system. Cells normally
encounter double-stranded RNA molecules like Ampligen and poly I
only during infection with RNA viruses. A receptor on the cell surface
called Toll-like receptor 3 (TLR3) is part of an evolutionarily
conserved family of “pattern recognition” receptors that detect
pathogens immediately, even those the body has not yet encountered,
long before adaptive immunity can intervene against foreign invaders.
These molecules are critical to the first line of immunological
defense against a broad range of pathogens, such as viruses, and even
various forms of cancer.

When TLR3 senses a dsRNA, it relays a message to the cell to produce
interferon, a small protein that serves as a signal. Interferon alerts
other cells that an infection is present and produces a series of
responses in nearby cells and the interferon-producing cell. These
include changes in gene regulation, for example stimulating production
of the 2'-5' oligoadenylate synthetase-dependent enzyme RNase L
(Ribonuclease, latent). This protein degrades viral RNA. It can also
degrade the cell's own RNA, leading to the apoptosis (programmed cell
death) of virally compromised cells.

The mechanism of Ampligen in relation to CFS is not known, but it is
thought to involve RNase L. Accumulation of an inactive form of RNase
L may be associated with CFS.[11] According to a Hemispherx press
release[1] summarizing findings[12] published in the Journal of
Immunology, Ampligen requires TLR-3 to work, in contrast on other
synthetic dsRNA molecules that are detected by multiple cellular
sensors.

[ 本帖最后由 葉芬 于 4-6-2009 09:28 AM 编辑 ]

葉芬

Clinical trials and approval status
A randomized study of Ampligen (AMP 516 Phase III clinical trial for
treatment of CFS) in the USA was completed in 2004.[13] The AMP 511
open label study of Ampligen in CFS is still recruiting participants.
[14] Open label studies are typically used when the controlled trial
has ended and treatment is continued so that the subjects and the
controls may continue to receive the benefits of the investigational
drug until marketing approval is obtained.[15] Hemispherx management
had missed several target deadlines for new drug application (NDA)
filing in the past, including the end of 2005, the third quarter of
2006, and the first quarter of the year 2007.[16] In October 2007, the
US Food and Drug Administration (FDA) Ampligen NDA was filed, but
marketing for the treatment of CFS has not yet been approved.[1][2]
Ampligen is received intravenously. It is generally administered twice
weekly for periods of one year or greater. Two toxicology studies were
recently completed that establish the safety of intranasal and
intramucosal methods of Ampligen administration.[17] Hemispherx states
it is currently researching an oral drug that uses nucleic acid
technology related to Ampligen.[18]

impact
Approximately 760 patients have received Ampligen as part of clinical
trials in the US, representing about 75,000 doses. Some Chronic
Fatigue Syndrome patients have reported a complete recovery, with
others reporting clear and measurable improvements [19], although
success has not been universal. More common benefits include improved
cognitive skills, an increase in energy, and greater oxygen uptake.
These improvements can be measured on the Karnofsky scale [20][21].
Some studies suggest that Ampligen is most effective against a certain
subset of CFS patients, those with severe debilitation[citation
needed]. According to Dr Paul Cheney, a CFS researcher, the chances of
a response appear to be "2 chances in 3 and that might be raised a
little bit if one targets a subset of patients, specifically ones that
are within the first 5 years of their illness who have abrupt onset
and who may have activation of this RNase L pathway" [22].

In December, 2006, Hemispherx reported results of a completed Phase 3
trial, in which chronic fatigue syndrome patients receiving Ampligen
for 40 weeks “improved exercise treadmill performance 14.8% in the
placebo group (p=0.025) and 13% by intent to treat analysis (p=0.052).
The Ampligen group improved oxygen utilization by 6.1% v 0.58% in the
placebo group (p<0.05, single-sided). The correlation with treadmill
exercise duration in patients treated with Ampligen was highly
significant (p<0.0001). The KPS (Karnofsky performance score), a
function of general physical capacity, was also significantly
correlated (<0.01) with the improvement in exercise tolerance of the
Ampligen study arm … The concomitant use of drugs with Ampligen or
placebo was reduced significantly in the Ampligen arm of both the
Phase 2 and Phase 3 trials.”[1]

Side effects and safety
Hemispherx consider that Ampligen has been "generally well tolerated",
with a "low incidence of clinical toxicity", particularly when
compared to the toxicity of the diseases it is used to treat. "No
serious safety issues have resulted from the administration of ~75,000
doses IV (most commonly 400 mg) twice weekly for up to one year
periods or greater. Animal toxicity studies support this observation
in humans with primates demonstrating the greatest margin of
safety."[23] A mild flushing reaction has occurred in about 15% of
patients, and other reported side effects include chills, fever,
malaise, leukopenia, neutropenia and leukocytosis. A full list is
available on the Hemispherx website.[24] The extent of these side
effects is unknown. According to Hemispherx, side effects usually
subside within "several months".

One patient with CFS in the San Diego Ampligen study committed suicide
during the clinical trial. Another quit because of serious side
effects.[citation needed]

Controversy
Manuel Asensio, an investment adviser who reports on companies he
considers to be overvalued, has criticized Hemispherx and its Ampligen
results, [25] alleging a variety of misdemeanors including accusations
of refusing to supply Ampligen after clinical trials have ended [26],
and issuing misleading results to widen markets for Ampligen [25].

In 1998, Hemispherx Biopharma filed a complaint against Asensio and
his company, alleging defamation, conspiracy, and interference with
its business relations through a short selling plot. After a jury
rejected the defamation claims against Asensio, a mistrial was
declared. Hemispherx announced in 2006 that they anticipated a new
trial date to be set[27].

韦一笑

最近医药股都不错成绩哦

SUNNY仔

原帖由 葉芬 于 3-6-2009 04:06 PM 发表
對不起啊 Jochen，第一帖的HEB卡到
所以我從新開過一帖，希望你不介意。

資料 from m.i.k.e.

HEB 股东名单
wobushi  200
napster 5000
miku  0 （2/6/09 賣出）
blazechee 1000
cschia ...

芬姐..虽然大家姓叶..但别酸我啦..上几个星期已ADD HEB进去WATCH LIST了..但没进场...反而高价($1.80)再进了5000 CTIC.. ..MGM的1300UNIT本来拿来平衡$8.73和$8.75买进的2200也卖了,卖价是$7.80X1300...赚了八百多新币..可以去吃麦当当了...
这几天HEB大起大落..看了也心慌...

葉芬

原帖由 SUNNY仔 于 4-6-2009 01:38 PM 发表


芬姐..虽然大家姓叶..但别酸我啦..上几个星期已ADD HEB进去WATCH LIST了..但没进场...反而高价($1.80)再进了5000 CTIC.. ..MGM的1300UNIT本来拿来平衡$8.73和$8.75买进的2200也卖了,卖价是$7.80X1300...赚了八 ...

呵呵 CTIC 也不錯。
不過還要等一陣子才能Hit雙位數。

HEB呢...要是Approval今晚出，HEB Hit雙位數就是在今晚囉。
祝大家好運。

[ 本帖最后由 葉芬 于 4-6-2009 04:01 PM 编辑 ]

葉芬

不錯的文章，關于HEB的。。

http://www.stockshaven.com/hemispherx-ampligen-combats-h5n1/

napster

大家有查自己的selling limit?.
不然今晚hit＄25也卖不出
我selling limit SGD95000，如果hit到＄25就卖不完了

不好意思叫broker提高到＄150000

葉芬

原帖由 napster 于 4-6-2009 05:05 PM 发表
大家有查自己的selling limit?.
不然今晚hit＄25也卖不出
我selling limit SGD95000，如果hit到＄25就卖不完了

不好意思叫broker提高到＄150000

我的Selling Limit 是85000新元。
不過要是真的Hit到US$25，我會賣半粒。
半粒先2星期後再賣半粒。

今天的CTIC Pre-Market Up 0.12 =  1.90 。
不錯。

[ 本帖最后由 葉芬 于 4-6-2009 06:11 PM 编辑 ]